Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2022 07:00 ET | Source: NMD Pharma

NMD Pharma expands its US presence

PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...
June 30, 2021 07:00 ET | Source: NMD Pharma

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
June 30, 2021 02:00 ET | Source: NMD Pharma

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
July 14, 2020 07:00 ET | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
July 14, 2020 02:00 ET | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...